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Background: HIV and SIV generally require CD4 binding prior to coreceptor engagement, but Env can acquire the
ability to use CCR5 independently of CD4 under various circumstances. The ability to use CCR5 coupled with
low-to-absent CD4 levels is associated with enhanced macrophage infection and increased neutralization sensitivity,
but the additional features of these Envs that may affect cell targeting is not known.
Results: Here we report that CD4-independent SIV variants that emerged in vivo in a CD4+ T cell-depleted rhesus
macaque model display markedly decreased plasticity of co-receptor use. While CD4-dependent Envs can use low
levels of macaque CCR5 for efficient entry, CD4-independent variants required high levels of CCR5 even in the
presence of CD4. CD4-independent Envs were also more sensitive to the CCR5 antagonist Maraviroc. CD4-dependent
variants mediated efficient entry using human CCR5, whereas CD4-independent variants had impaired use of human
CCR5. Similarly, CD4-independent Envs used the alternative coreceptors GPR15 and CXCR6 less efficiently than
CD4-dependent variants. Env amino acids D470N and E84K that confer the CD4-independent phenotype also regulated
entry through low CCR5 levels and GPR15, indicating a common structural basis. Treatment of CD4-dependent Envs
with soluble CD4 enhanced entry through CCR5 but reduced entry through GPR15, suggesting that induction of
CD4-induced conformational changes by non-cell surface-associated CD4 impairs use of this alternative co-receptor.
Conclusions: CD4 independence is associated with more restricted coreceptor interactions. While the ability to enter
target cells through CCR5 independently of CD4 may enable infection of CD4 low-to-negative cells such as macro-
phages, this phenotype may conversely reduce the potential range of targets such as cells expressing low levels of
CCR5, conformational variants of CCR5, or possibly even alternative coreceptors.Background
During HIV and SIV entry, gp120 engagement of CD4 is
normally required to initiate the conformational changes
in Env that form and expose a coreceptor binding site,
which then allows CCR5 engagement and subsequent
entry steps to occur [1,2]. Although extremely rare in
natural infection in vivo, several pathways have been de-
scribed by which HIV and SIV can adapt to use CCR5 in
the presence of little-to-no CD4 [3-9]. The factors that
serve to restrain CD4 independence during normal in-
fection, and their relationship to coreceptor use and
entry, have important implications for cell targeting and
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reproduction in any medium, provided the orWe recently described a unique SIV model in which
such CD4-independent Env variants emerged and domi-
nated in the plasma of multiple rhesus macaques experi-
mentally depleted of peripheral (but not mucosal) CD4+
T cells prior to infection [9,10]. These animals displayed
widespread infection of tissue macrophages, which ex-
press very low levels of CD4 compared to CD4+ T cells,
indicating a mechanism by which virus could expand its
target cell range in this setting of limited CD4+ T cell
targets. The CD4-independent Env variants that arose in
CD4+ T cell depleted macaques were highly sensitive to
antibody neutralization, a characteristic that is common
among previously-described CD4-independent HIV and
SIV [5-8]. Unlike the CD4-independent Envs that were
constitutively sensitive to neutralization by normal SIV +
plasma and monoclonal antibodies, CD4-dependent con-
trol Envs became sensitive only if first incubated withal Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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to produce this CD4-inducible neutralization activity,
however, enabling emergence of CD4-independent vari-
ants in these animals. These findings, along with other
studies [5-8], suggest that antibodies shape the cellular
tropism of the virus in vivo by preventing the emergence
of CD4-independent variants during typical infection.
Both CD4 independence and neutralization sensitivity
were conferred by D470N/E84K mutations in Env that
arose in these animals [9], indicating that these are linked
phenotypes resulting from a common structural basis.
In this study, we wished to determine whether there
were additional biological features of CD4-independent
Envs that arise in this model that, in addition to sensitiv-
ity to antibody neutralization, might affect cell entry and
targeting, and thus impact emergence of such variants.
It has previously been reported that some HIV isolates
that can enter cells using low levels of CD4 may be lim-
ited in their capacity to efficiently engage low levels of
CCR5 [11,12]. Since most CD4+ T cells express relatively
low levels of CCR5 [13-17], this property could impact
cell targeting by restricting infection in vivo to the lim-
ited subset of cells expressing high levels of CCR5. In
addition, CCR5 is expressed on primary cells in a variety
of conformational forms, suggesting that efficient infec-
tion may require some degree of plasticity in Env func-
tion that allows it to interact with such conformational
variants [18-20]. Thus, seeking to understand whether
more restricted coreceptor use might be a factor, in
addition to immune pressure, that could limit the emer-
gence of CD4-independent Env in vivo, we tested our
panel of plasma-derived CD4-independent Envs for their
ability mediate entry using low-level CCR5, using human
CCR5, and using the alternative coreceptors GPR15 and
CXCR6. Low-level CCR5 clearly reflects a biologically
important feature of primary target cells in vivo [13-15],
while use of the human CCR5 molecule and of alternative
coreceptors [21,22], may reflect a degree of “plasticity” by
which Env can function using related but structurally
distinct molecules.
Here we report that CD4-independent SIV Env vari-
ants that arise in vivo are impaired in their ability to use
low levels of rhesus macaque CCR5 for entry even in the
presence of CD4. Furthermore, they are significantly less
efficient in use of human CCR5, and rhesus macaque
GPR15 and CXCR6, than are CD4-dependent control Envs.
Loss of coreceptor plasticity was conferred by the same
molecular determinants that regulate CD4-independence,
indicating a shared structural basis. These findings suggest
that CD4-independent variants may have an expanded
capacity for infection of CD4-low targets, but may have an
otherwise narrower range of potential cellular targets
in vivo due to more limited ability to infect CCR5-low cells
and/or cells expressing CCR5 conformational variants.Thus, in addition to neutralization sensitivity, a more
restricted coreceptor utilization capacity may also serve to
limit the emergence of CD4-independent variants during
normal infection.
Results
CD4-independent SIV Envs have reduced capacity
compared to CD4-dependent Env to use human CCR5
We previously described a model for in vivo emergence
of CD4-independent SIV in which rhesus macaques were
experimentally depleted of CD4+ T-cells before SIV-
mac251 infection [9,10]. Envs isolated from the plasma of
CD4+ T cell-depleted animals at day 42 (d42) post infec-
tion were capable of mediating infection using CCR5
independently of CD4, while Envs from CD4+ T cell-
depleted macaques early after infection and control
macaques both early and late after infection were strictly
CD4-dependent [9].
To understand the features of CD4-independent Envs,
we focused on 23 CD4-independent Envs from d42
plasma of four CD4+ T cell-depleted animals and 12
CD4-dependent Envs from d42 plasma of two control
animals. As shown in Figure 1A, the CD4-independent
Envs mediated equivalent levels of pseudotype virion
entry into 293 T cells transfected with rhesus macaque
CCR5 (rmCCR5) with and without rmCD4, whereas the
control Envs were CD4-dependent. In addition, CD4-
dependent and CD4-independent Env variants had
equivalent levels of entry overall into cells expressing
both rmCD4 and rmCCR5. Thus, the CD4-independent
Envs are as efficient as CD4-dependent Envs at mediat-
ing entry using rmCCR5 in this transfection system, and
are essentially indifferent to the presence or absence of
CD4 when entering through rmCCR5.
In contrast to entry using RM receptors, the CD4-
independent Envs were significantly less efficient than
CD4-dependent Envs in entering cells expressing human
CCR5 and CD4 (Figure 1B). The lower overall entry
using human receptors was due to less efficient use of
human CCR5, as entry in the presence of rmCCR5/
huCD4 was as efficient as entry in the presence of
rmCCR5/rmCD4, and entry using huCCR5/rmCD4 was
similar to huCCR5/huCD4 (data not shown). The CD4-
independent Envs were CD4-independent on human
CCR5, although entry was lower in cells expressing
huCCR5 alone compared to huCCR5/huCD4. Thus, the
CD4-independent Envs are attenuated in their use of
huCCR5 compared to CD4-dependent Envs.
We further examined whether the CD4-independent
phenotype we observed during infection of cells over-
expressing CCR5 also applied to primary cells, and
whether the CD4-independent Envs were less efficient
than CD4-dependent Envs in huCCR5 use in the context
of primary cells (Figure 1C). Primary human PBMCs
Figure 1 Lower efficiency of human CCR5 use by CD4-independent compared to CD4-dependent SIV Envs. Pseudotyped viruses carrying
Envs from d42 CD4+ T cell depleted macaques (CD4-independent Envs; open circles) or control macaques (CD4-dependent Envs; closed circles)
were used infect 293 T cells transfected with receptor molecules (A,B) or primary human PBMCs (C). (A) 293 T cells were transfected with rhesus
macaque (RM) CCR5 with or without rhesus CD4 and infected with pseudotype viruses. Entry was assessed based on luciferase production
72 hours after infection and expressed as relative light units (RLU). (B) SIV Env-pseudotyped viruses were used to infect 293 T cells transfected
with human CCR5 with or without human CD4. (C) Envs were assessed for their ability to mediate viral entry into PHA/IL2-stimulated human
PMBCs that were pre-treated with or without a CD4 blocking antibody (mAb #19). Unpaired T-tests were used to compare entry between the 2
sets of Envs in a given target cell type, while paired T-tests were used to compare entry of Envs in the presence versus absence of CD4.
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body #19, which blocks CD4-dependent HIV and SIV
entry [23]. As expected, entry into PBMCs by CD4-
dependent Envs was reduced to background levels by
mAb #19, whereas CD4-independent variants were largely
resistant to entry blockade by #19, confirming that the
CD4-independent phenotype extends to primary cells as
well. Overall entry by CD4 independent viruses (in theabsence of mAb #19) was attenuated compared to CD4-
dependent Envs, which stands in contrast to the equiva-
lent entry into rmCCR5/rmCD4 transfected cells for the
CD4-independent and –dependent viruses (Figure 1A),
but is similar to lower entry for the CD4-independent vi-
ruses into huCCR5/huCD4 transfected cells (Figure 1B).
Thus, CD4-independent variants are also less efficient
than control Envs at entry into human CCR5/CD4-
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independent viruses likely reflects less efficient use of hu-
man CCR5, but since primary cells express CCR5 at lower
levels than transfected cells, could also reflect inefficient
use of lower levels of coreceptor compared with CD4-
dependent Envs.
CD4-independent SIV Envs use low levels of rmCCR5 less
efficiently than CD4-dependent Envs
To address the impact of CCR5 expression levels, we
tested the ability of CD4-independent SIV Env variants
to mediate entry into 293 T cells transfected with various
amounts of rmCD4 and rmCCR5 (Figure 2). Flow cy-
tometry analysis showed that transfection of 0.0, 0.01,
0.1, or 1.0 μg rmCCR5 plasmid resulted in mean fluores-
cence intensity (MFI) levels of approximately 5, 6, 10,
and 29, respectively, while transfection with 0.0, 0.1, or
1.0 μg rmCD4 plasmid resulted in MFI levels of 4, 9,
and 15, respectively (data not shown), confirming that
varying plasmid transfection results in correspondingly
varying levels of receptor surface expression.
As expected, CD4-dependent control Envs exhibited
high infectivity at high levels of CCR5, which gradually
dropped at lower levels of CCR5 (Figure 2A). In con-
trast, CD4-independent Envs exhibited a steep decline
in infectivity even at slightly reduced levels of CCR5Figure 2 CD4-independence is associated with reduced ability to use
their ability to infect 293 T cells transfected with different amounts of rmCD4
CD4-dependent (A) and CD4-independent (B) Envs. The horizontal (X) axis in
depth (Z) axis indicates the amount of transfected CD4 decreasing from back
at entry in the presence of maximal rmCD4 and rmCCR5. (C) The panel of En
entry (no CD4, maximal rmCCR5) and Y axis indicating entry via low CCR5 (m
as a single point on the plot. Linear regression analysis was used to assess the(Figure 2B). We then analyzed a larger panel of Envs with
this assay, and determined the relationship between CD4-
independence and the ability to use low levels of CCR5
(Figure 2C). This analysis revealed a strong inverse correl-
ation between entry into cells expressing low levels of
rmCCR5 (in the presence of CD4) and entry into cells ex-
pressing high levels of rmCCR5 without CD4 (p = 0.001).
These results indicated that among SIV Env variants that
arise in vivo in infected macaques, CD4-independence is
strongly associated with inefficient use of low levels of
CCR5, even in the presence of CD4.
CD4-independent Envs show increased sensitive to the
CCR5 inhibitor Maraviroc
Sensitivity to small molecule inhibitors of CCR5 is often
used as a surrogate for efficiency of Env-CCR5 interac-
tions, with less efficient interactions associated with
greater sensitivity [14]. We therefore tested whether the
CD4-independent Envs would differ from CD4-dependent
Envs in sensitivity to the CCR5 inhibitor maraviroc. Target
293 T cells were transfected with rmCD4 and rmCCR5,
pre-treated with or without varying concentrations of
maraviroc, and infected with Env-pseudotyped viruses.
As shown in Figure 3, maraviroc inhibited entry of
CD4-dependent and CD4-independent Envs in a dose-
dependent manner, as expected. However, there was alow levels of rmCCR5. SIV Env-pseudotyped viruses were tested for
and rmCCR5. (A,B) 3D plots showing entry by representative
dicates the amount of transfected CCR5 decreasing from left to right, the
to front, and the vertical (Y) axis indicates the level entry with 100% set
vs were tested as in A and B, with the X axis indicating CD4-independent
aximal rmCD4 but only 10% of maximal rmCCR5). Each Env is indicated
correlation between CD4-independent entry and low-CCR5 entry.
Figure 3 Maraviroc sensitivity of CD4-independent Envs. Pseudotyped viruses carrying CD4-independent (dotted lines) or control (solid lines)
SIV Envs were tested for sensitivity to inhibition by maraviroc. Target cells were 293 T cells transfected with high levels of rmCD4 and rmCCR5
(1 μg each) and treated with various concentrations of maraviroc for 1 hour prior to and during infection.
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showing markedly greater sensitivity than all of the CD4-
dependent Envs (p < 0.01 by Wilcoxon rank-sum test).
Thus, like the less efficient use of low level CCR5, CD4-
independent Envs are impaired in their ability to use
CCR5 in the presence of a small molecule antagonist.
Decreased efficiency of GPR15 and CXCR6 use by
CD4-independent Envs
In addition to CCR5, several other G protein-coupled re-
ceptors can be used as entry co-receptors by SIV
in vitro, reflecting a substantial degree of plasticity in the
molecules with which these Envs can interact. To deter-
mine whether the efficiency of alternative coreceptor use
differed between CD4-dependent and independent Envs,
we assessed their ability to enter cells transfected with
either the orphan receptor GPR15 or the chemokine re-
ceptor CXCR6, in conjunction with CD4 (Figure 4).
CD4-dependent control Envs mediated efficient entry
into rmGPR15/rmCD4-expressing cells, reaching a mean
of 61% (range 40-80%) of entry compared to rmCCR5/
rmCD4, which confirms that GPR15 is used by these
SIVmac251 variants. However, CD4-independent Envs
were significantly impaired in their use of GPR15 com-
pared to control Envs (mean of 30%; range 2-60%). Re-
gression analysis showed a highly significant inverse
correlation between the ability of Env to use CCR5 in
the absence of CD4 and the ability to use GPR15 in the
presence of CD4 (p < 0.0001; Figure 4C), indicating that
CD4 independence is associated with decreased effi-
ciency of GPR15 use.
Consistent with previous studies [21], most SIVmac
Envs used rmCXCR6 poorly compared to CCR5 and
GPR15 (Figure 4C). Entry mediated by control Envs into
rmCXCR6/rmCD4-expressing cells reached a mean of
23% (range 10-60%) of entry compared to rmCCR5/rmCD4.Similar to GPR15, CD4-independent Envs were signifi-
cantly impaired in their use of CXCR6 (mean of 10%;
range 0-35%). Regression analysis showed a highly signifi-
cant inverse correlation between the ability of Env to use
CCR5 in the absence of CD4 and the ability to use CXCR6
in the presence of CD4 (p = 0.0002; Figure 4D), indicating
that CD4 independence is also associated with decreased
efficiency of CXCR6 use.
D470N and E84K regulate efficiency of low-CCR5 use and
GPR15 use
Since the CD4-independent variants were all derived
from plasma of macaques experimentally depleted of
CD4+ T cells prior to infection, the decreased efficiency
of alternative coreceptor and low-CCR5 use among
these variants could conceivably have resulted from se-
lective pressures on these Envs in vivo unrelated to their
CD4-independent phenotype. Therefore, in order to ask
whether CD4 independence and decreased low-CCR5
and alternative coreceptor use were inextricably linked,
we asked whether the molecular determinants of CD4-
independence also regulated these characteristics. We
recently identified two amino acids that emerged in the
CD4+ T cell-depleted macaque Envs that conferred CD4
independence when introduced into CD4-dependent
Envs (D470N, E84K), and which abrogated CD4 inde-
pendence when reverted in the CD4-independent Envs
[9]. E84K and D470N led to charge changes in and
around the predicted CD4-binding site in gp120, with
D470N introducing a potential N-linked glycosylation
site that was important for CD4-independent entry. As
individual mutations E84K and D470N each contrib-
uted to the CD4-independent phenotype but attenu-
ated overall entry, whereas together they conferred
robust entry in the presence of rmCCR5 both with
and without CD4 [9].
Figure 4 Reduced entry using GPR15 and CXCR6 by CD4-independent Envs. Env-pseudotyped viruses were tested for their ability to infect
cells transfected with rmCD4 and either rmGPR15 or rmCXCR6. (A,B) Entry into 293 T cells transfected with rmCD4 and either rmGPR15 or
rmCXCR6 was measured for each Env, and is indicated as a percentage of entry by that Env using rmCCR5 and rmCD4. (C,D) Envs from (A) or
(B) were plotted showing entry in cells transfected rmCCR5 without CD4 on the X axis, and entry into cells transfected with rmCD4 and either
rmGPR15 (C) or rmCXCR6 (D) on the Y axis. Each Env is indicated as a single point on the plot, and linear regression analysis was performed to
assess the relationship between CD4-independent entry and GPR15 or CXCR6 use.
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Envs, they conferred CD4 independence but markedly
reduced the ability of virons to enter into cells express-
ing low levels of rmCCR5 even in the presence of CD4
(Figure 5A,B,E). Conversely, when N470D and K84E
were introduced into CD4-independent Envs, they re-
duced the ability to utilize rmCCR5 independently of
CD4, but enhanced the ability to utilize low levels of
rmCCR5 in the presence of CD4 (Figure 5C,D,E). K84E/
N470D did not completely restore use of low CCR5 to
the level of CD4-dependent Env (Figure 5E), suggesting
that additional determinants may also contribute to effi-
ciency of CCR5 use. Finally, introduction of D470N and
E84K into control Envs reduced use of rmGPR15, while
N470D and K84E enhanced rmGPR15 use (Figure 5F).
Thus, the molecular determinants that regulate CD4-inde-
pendent use of CCR5 are also the molecular determinants
of co-receptor use plasticity, indicating that they are
linked properties of these Envs, rather than independent
but co-selected phenotypes of virus variants that emerged
in these animals.
Conformational changes induced by soluble CD4 inhibit
GPR15 use
Envs capable of using CCR5 in the absence of CD4 are
thought to constitutively exist in a CD4-triggered con-
formation. Previous studies have shown that solubleCD4 (sCD4) does not efficiently inhibit SIV, and indeed
is capable of triggering conformations in SIV Env that
enable entry using CCR5 in the absence of CD4 [24,25].
To determine if sCD4 triggering has an effect on use of
GPR15 similar to the CD4-independent phenotype, we
tested the impact of sCD4 on the ability of CD4-
dependent control Envs to mediate entry using rmGPR15/
CD4. As shown in Figure 6, sCD4 pre-triggering enabled
entry by CD4-dependent control Envs into cells express-
ing rmCCR5 in the absence of CD4, and slightly enhanced
entry into cells expressing rmCCR5/CD4. In contrast,
sCD4 treatment resulted in a significant (~50%) reduction
in entry using rmGPR15/CD4 (Figure 6C), which is simi-
lar to the relative deficiency in GPR15 use by CD4-
independent compared with control Envs (Figure 4A).
Treatment of CD4-independent Envs with sCD4 had no
impact on their ability to mediate entry using rmCCR5,
with or without CD4, nor on their relative lack of ability
to use rmGPR15/CD4. Thus, even though cell surface
CD4 engagement is required for GPR15-mediated entry,
CD4-induced conformational changes in Env that occur
independent of cell surface CD4 inhibit the use of GPR15,
concordant with the reduced ability of CD4-independent
Envs to use GPR15 compared with CD4-dependent Envs.
Notably, sCD4 did not inhibit entry mediated by control
Envs in the presence of rmCCR5/CD4, suggesting that its
inhibition of entry in the presence of rmGPR15/CD4 was
Figure 5 (See legend on next page.)
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Figure 5 Env D470N and E84K determine efficiency of CCR5 and GPR15 use. Mutations that emerged in vivo which conferred CD4 independence
(D470N and E84K) were introduced into CD4-dependent Envs, and mutations that abrogate CD4 independence (N470D and K84E) were introduced into
CD4-independent Envs. (A-D) Two representative parental CD4-dependent Envs (A) and their respective mutated forms (B) and two representative
parental CD-independent Envs (C) and their respective mutated forms (D), were assessed for their ability to mediate entry into cells transfected with
varying amounts of rmCCR5 and rmCD4, as described in Figure 2. (E) Use of low rmCCR5 levels by all parental and mutant Envs (10% maximal CCR5 in
the presence of maximal CD4), with each Env indicated as a dot and entry in the presence of maximal CCR5/CD4 set at 100%. (F) Use of GPR15 by
parental and mutated Envs were tested based on entry into cells transfected with rmGPR15 and rmCD4, with each Env indicated as a dot and expressed
as a percentage of entry in the presence of rmCCR5/rmCD4.
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or similar mechanisms. Thus, sCD4 inhibition of entry
using GPR15 is likely due to effects on gp120 interactions
with the coreceptor.
Discussion
We focused here on a panel of SIV Envs derived from
the plasma of rhesus macaques that had been experi-
mentally depleted of CD4+ T cells prior to infection, in
which CD4-independent virus variants arose in multiple
animals in association with widespread macrophage in-
fection. The ability to use CCR5 in conjunction with
low-to-absent CD4 is a common feature of viruses that
efficiently infect macrophages, which express extremely
low levels of CD4. However, while entry by these viruses
using high levels of rmCCR5 in transfected cells is very
efficient with or without CD4, the Envs display de-
creased efficiency of entry in four areas: ability to use
low levels of CCR5; ability to use the human homologue
of CCR5; sensitivity to a CCR5 entry inhibitor; and use
of the alternative coreceptors GPR15 and CXCR6. Be-
cause these features are all tightly linked, we suggest that
they reflect a common property of overall decreased
“plasticity” of Env-coreceptor interactions, as a conse-
quence of having acquired the ability to use CCR5 with-
out CD4.
While multiple reports have described CD4-independent
SIV and HIV generated in various model systems, strict
CD4 dependence is a general rule for viruses in vivo dur-
ing normal infection. Understanding the consequences of
CD4 independence in settings where it is acquired, there-
fore, provides insight into critical factors that maintain
CD4 dependence in normal infection. We previously re-
ported that the CD4-independent variants in these ani-
mals are highly sensitive to neutralization by SIV + plasma
and several monoclonal antibodies, similar to other CD4-
independent variants described [5-9], whereas control
Envs are resistant to neutralization unless pre-triggered by
sCD4. Since the CD4+ T cell depleted animals in which
these variants arose failed to produce such CD4-inducible
neutralizing activity, one clear factor that appears to con-
tribute to maintaining CD4 dependence is avoidance of
plasma neutralization. However, our findings here that
CD4-independent Envs exhibit more restricted coreceptoruse suggest that additional factors may also impact func-
tion of CD4-independent Envs and regulate their relative
fitness in vivo.
We found that CD4 independence is linked to defective
use of low levels of CCR5 both phenotypically (Figure 2C)
and structurally (Figure 5A-E). Decreased ability to use
low levels of available CCR5 may also underlie CD4-
independent Envs increased sensitivity to maraviroc
(Figure 3 and [14]). In contrast to the CD4+ T cell de-
pleted model in which these viruses arose, where a shift
towards macrophage targets occurred, CD4+ memory T
cells are the principal targets of HIV and SIV in normal
infection. In general, CCR5 is expressed on CD4+ T cells
at relatively low levels, in contrast to much higher expres-
sion on macrophages [15,16,26]. Indeed, low CCR5 ex-
pression is considered to be a principal factor limiting
entry into CD4+ T cells [17], but not into macrophages,
whereas low CD4 expression limits macrophage infection
[27]. While the relationship between CCR5 density on pri-
mary macaque macrophages and lymphocytes compared
with transfected 293 T cells has not been specifically de-
fined, our data suggests that a loss of CCR5 efficiency ac-
companies CD4 independence among these Envs, which
likely affects low-CCR5 but not high-CCR5 targets. Thus,
while CD4 independence may enable the virus to infect an
expanded range of CD4-low cell types, particularly macro-
phages, a consequence of this feature may be a restricted
capacity to infect primary CD4+ T cells expressing low or
moderate levels of CCR5.
CD4 independence of these Envs was also linked to
less efficient use of human CCR5, despite equivalent
entry in the presence of high levels of transfected
rmCCR5 (Figure 1). In addition to overall lower levels of
expression, CCR5 on primary CD4+ T cells exists in a
range of structural conformations, which is reflected in
conformational antibody and/or Env binding characteris-
tics [16,17,19]. It has been previously suggested that the
ability to engage alternative conformations of CCR5, or
even the capacity to engage ligand-bound receptor, en-
ables Env to more efficiently use the heterogeneous
conformations that are expressed on CD4+ T cells
[13-15,18-20]. CCR5 of human and macaque origin share
97.7% amino acid identity [28], and Env use of the two ho-
mologues is generally highly concordant. However, our
Figure 6 Reduced use of GPR15 by SIV Envs pre-triggered with sCD4. Pseudotype viruses carrying CD4-dependent or CD4-independent Envs
were incubated with or without sCD4 (50 ug/ml for 1 hour) and assessed for their ability to infect cells 293 T cells expressing rmCCR5 and rmCD4
(A), rmCCR5 without CD4 (B), or rmGPR15 and rmCD4 (C). Each Env is indicated as a box (without sCD4) and a triangle (with sCD4), and the two
conditions for each individual Env are connected by a line. Paired T-tests were used to compare entry with and without sCD4 incubation.
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paired in use of huCCR5 compared with control Envs sug-
gests that they are more sensitive to subtle structural
variations in the molecule. We speculate that the greater
use of huCCR5 that we observed in CD4-dependent Envs
compared to CD4-independent Envs may reflect a greater
ability to tolerate structural variations, which might allow
these Envs to effectively engage CCR5 on a broader range
of CD4+ T cells. Thus, in addition to restricted use of low
levels of CCR5, reduced plasticity of coreceptor use may
also result in a limited tolerance for structural variation,and thus a more limited range of CD4+ T cell targets for
CD4-independent viruses.
The CD4-independent Envs in our study also dis-
played impaired entry into cells expressing rmGPR15
and rmCXCR6 compared to control CD4-dependent
Envs, even in the presence of CD4. SIV Envs typically
use a range of alternative coreceptors in vitro. However,
while alternative entry pathways are used in vivo in non-
pathogenic infection of sooty mangabey and red-capped
mangabey natural hosts [29,30], it is unclear whether
any of these pathways, including GPR15 and CXCR6,
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[21,22], and there appears to be no consequence in vivo to
loss of GPR15 utilization [22]. Thus, while we cannot
completely exclude the possibility that less efficient GPR15
and CXCR6 use by CD4-independent variants may limit
infection of GPR15+ or CXCR6+ cells in vivo, we think it
is more likely that this feature reflects simply another as-
pect of the overall more coreceptor-constrained, less plas-
tic function of the CD4-independent Envs.
Our observation that the ability of SIV to enter inde-
pendently of CD4 correlates inversely with efficiency of
CCR5 use differs from some previous studies that exam-
ined variants with the capacity to use exceedingly low
levels of CD4 for entry, which were in some cases also
better able to utilize low levels of CCR5 [31-34]. In those
studies, the ability to scavenge very low levels of CD4 on
the cell surface was thought to result from increased af-
finity for CD4, or more stable interactions, thus more ef-
ficiently triggering the CD4-induced conformational
changes that enable coreceptor engagement [35]. In con-
trast to those studies, our CD4-independent variants
were not sensitive to inhibition by sCD4 (Figure 6A) and
could function in the complete absence of CD4 in the
context of high rmCCR5 expression (Figure 1A). It ap-
pears that our CD4-independent variants exist constitu-
tively in or spontaneously acquire the CD4-bound
conformation, even in the absence of CD4 [9]. There-
fore, loss of coreceptor use plasticity may be specific to
Envs that have a pre-formed or spontaneously exposed
coreceptor binding site [5-8] rather than Envs that scav-
enge low levels of CD4 on the cell surface [3,4,31-34].
Taken together, these data suggest that diverse mecha-
nisms exist by which virus can expand its host range
into CD4-low or negative cells, which may have different
consequences for coreceptor interactions. Nevertheless,
because these variants arose and came to dominate
plasma virus in multiple animals, this mechanism re-
flects a bona-fide pathway of evolution in this CD4+ T
cell depleted model that highlights factors impacting
Env function. Whether similar decreased plasticity of
coreceptor use is a feature shared by CD4-independent
Envs that emerge in other models will be an interesting
topic of future studies.
Conclusion
In conclusion, we have identified loss of coreceptor use
plasticity as a potential consequence of CD4-independent
entry capacity. The depletion of CD4+ T cell targets in
our model likely forced the virus to adapt to a CD4-
independent phenotype to enable macrophage targeting,
in the permissive environment lacking antibody activity
that would otherwise neutralize these variants. An add-
itional consequence of this adaptation, however, is de-
creased ability to use low levels of CCR5 and related butdistinct coreceptor structures. As a result, even though
these variants have broadened their range of targets to in-
clude CD4-low/CCR5-high cells, they may have a para-
doxically narrower range of potential target cells among
CD4+ cells that express lower levels or conformational
variants of CCR5 such as primary CD4+ T cells. Under
normal circumstances, the targeting of such primary CD4+
T cells may be an additional factor that, along with im-
mune pressure, normally limits the emergence of CD4-
independent Env variants in vivo.
Methods
SIVMac envelope clones and receptor plasmids
The SIV env genes analyzed here were cloned by single
genome amplification from d42 plasma of SIV-infected
rhesus macaques, and mutations introduced using the
QuickChange II XL Site-Directed Mutagenesis Kit (Agilent,
Santa Clara, CA) and verified by sequencing, as previously
described [9,10]. Of 24 Envs cloned from d42 plasma of
CD4+ T cell-depleted macaques (animals RUf6, RUt5,
RPe6, and RZj5), 23 mediated entry in the absence of CD4
that was >50% of that in the presence of CD4, and were
considered “CD4-independent”. None of the 12 Envs
cloned from d42 plasma of control macaques (animals
RZu4 and KKE) mediated CD4-independent entry, and
were designated as CD4-dependent control Envs. Pseudo-
typed viruses carrying SIV Envs on the NL4.luc/env-/vpr+
HIV-1 backbone that has luciferase in place of nef [36]
were generated as previously described [37], and were
treated with DNAse prior to use.
Preparation of target cells
Human 293 T cells were maintained in DMEM contain-
ing 10% fetal bovine serum. Coreceptor-transfected tar-
get cells were prepared by transfecting 106 293 T cells
with 1 μg plasmid encoding co-receptor with or without
1 μg plasmid encoding CD4, using Fugene transfection
reagent (Promega, Madison, WI) as per manufacturer’s
instructions, and plasmid pcDNA 3.1 as “filler” to main-
tain a total of 2 μg plasmid per transfection. To prepare
target cells expressing variable levels of CD4 and CCR5,
106 cells were transfected with 1, 0.1, 0.01, or 0 μg plas-
mid encoding rmCCR5 along with 1, 0.1, or 0 μg plas-
mid encoding rmCD4, using pcDNA 3.1 as “filler”. One
day after transfection, target cells were re-plated into 96-
well plates (2x104 per well), and then infected the fol-
lowing day with pseudotyped viruses. In parallel, cells
transfected with varying levels of CD4/CCR5 were sub-
ject to FACS analysis for CCR5 and CD4 expression
using antibodies CD4 (L200)-FITC and CCR5 (3A9)-
APC (BD Pharmingen; Franklin Lakes, NJ). For mara-
viroc titration experiments, 293 T cells were transfected
with rmCCR5 and rmCD4 (1 ug each), and treated with
0.1, 1, 10, 100 μM maraviroc (Pfizer, Inc., provided by
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alone, for 1 hour prior to and during infection.
Primary human PBMCs from healthy volunteers were
cultured at 2x106 cells/mL in RPMI containing 10% fetal
bovine serum, stimulated with PHA (5 μg/mL) for 3 days,
and maintained thereafter with IL-2 (20 U/mL). On d. 4
after isolation, cells were plated at 105 cells per well in
96-well plates, incubated with or without the CD4 block-
ing mAb #19 (5 μg/ml; [23]), then infected with pseudo-
type viruses.
Infection of target cells
Target cells were infected with Env-pseudotyped viruses
(20 ng p24 antigen per virus) by spinoculation at 1200xg
for 2 hrs. Cells were then incubated for 72 hrs at 37°C
and infection was quantified by measuring luciferase
content in cell lysates as previously described [29]. All
data represent a minimum of 3 independent experi-
ments, each carried out in duplicate. Where appropriate,
entry of each virus into cells expressing the various com-
binations of CD4 and co-receptor was calculated as a
percentage of entry of that virus into cells expressing the
highest levels of CD4 and CCR5.
Soluble CD4-183 (sCD4; Pharmacia, Inc.) was ob-
tained from the NIH AIDS Reference Reagents Program,
and sCD4 exposure assays were performed essentially as
previously described [9]. Pseudotyped virus was mixed with
sCD4 to achieve a concentration of virus of 0.8 ng/μl of
viral p24 antigen and 50 ng/μl sCD4, and incubated at 37°C
for 1 hr. A volume of this mixture (or virus incubated
without sCD4) containing 20 ng p24 was used to infect
cells as described above.
Statistical analysis
Statistical analysis was conducted using GraphPad Prism
version 4.0c for Macintosh (GraphPad Software, San
Diego, CA). Paired T-tests on log-transformed data were
used to compare data sets where a single panel of Env var-
iants was tested for entry on 2 different target cell samples,
while unpaired T-tests were used for all other mean com-
parisons. Linear regression analysis was performed using
default parameters in Prism, without constraints and fit to
mean values. To calculate maraviroc sensitivity, sigmoidal
dose response curves and EC50s were generated in Prism,
and EC50s compared by Wilcoxon rank-sum test.
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